Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLA-haploidentical transplantation with alpha-beta T-cell and B-cell depletion in pediatric Fanconi anemia or severe combined immunodeficiency
jRCTs032230287Completed
- Sponsor
- National Center for Child Health and Development
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab and tacrolimus in Fanconi anemia (FA) and severe combined immunodeficiency (SCID), sponsored by National Center for Child Health and Development. Primary endpoints: Graft failure at 30 days after transplantation and Death up to 30 days after transplantation. Started Feb 2024; status: completed.
02
Drugs
rituximabtacrolimus
03
Conditions
Fanconi anemia (FA)severe combined immunodeficiency (SCID)
Beyond the preview
Go deeper on jRCTs032230287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs032230287.